NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
WALTHAM, Mass., March 22 Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") has granted the Company an extension to meet the Exchange's continued listing standards and become compliant. The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.
As previously disclosed, Interleukin Genetics received notice from the Exchange indicating that the Company is not in compliance with Section 1003(a)(i), (ii) or (iii) of the Company Guide.
While the Company is taking steps to regain compliance with all applicable requirements for continued listing on the Exchange by June 23, 2010, there can be no assurance that the company will be able to do so in such time frame, or at all.
About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health(Ū) brand including Bone Health, Weight Management, Heart Health and Nutritional Needs. The Company is headquartered in Waltham, MA. For more information please visit www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements, including statements regarding our ability to regain compliance with the NYSE Amex continued listing requirements by June 23, 2010. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2008, quarterly reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.
SOURCE Interleukin Genetics, Inc.
You May Also Like